# AI in nuclear medicine

Source: https://nuclide.cc/technologies/ai-in-nuclear-medicine/  
Nuclide record `ai-in-nuclear-medicine` (Technology). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Computer software trained on thousands of scans can now automatically outline tumours on PET and SPECT images in seconds instead of the 30-45 minutes it takes a doctor, though a specialist still checks the result.

## Summary

Artificial intelligence, predominantly convolutional neural networks and related deep-learning architectures, is being applied across nuclear medicine and radioligand therapy for automated lesion detection and segmentation, tumour-burden quantification, image denoising and reconstruction, CT-free attenuation/scatter correction, and early-stage dose-prediction and toxicity models. In PSMA PET, deep-learning segmentation tools (for example the aPROMISE platform) have matched inter-radiologist agreement for prostate-gland segmentation (Dice similarity coefficient around 0.89 versus an inter-radiologist DSC of about 0.91) while completing a scan in roughly 15 seconds compared with 30-45 minutes for manual contouring, and a comparative reader study against a standard PACS viewer found similarly high intra- and inter-reader agreement with both systems against histopathology as the reference standard, with the AI tool automatically segmenting about 92% of consensus lesions.

A 2026 structured narrative review across PSMA, somatostatin-receptor/PRRT, radioiodine and 90Y-radioembolisation platforms found the strongest direct evidence for AI-assisted segmentation, tumour-burden quantification and early dose-map prediction, but concluded that no platform yet has a prospectively validated, outcome-linked model for AI-guided treatment selection or activity prescription; independent, multicentre, external validation against dosimetric reference standards remains the key evidence gap. Test-retest repeatability studies of AI-derived PSMA tumour-volume metrics show acceptable reproducibility when the same tracer is used for both scans, but substantially wider limits when different PSMA tracers (for example 68Ga-PSMA-11 versus 18F-PSMA-1007) are compared, underscoring that AI outputs, like human-read metrics, are tracer- and protocol-dependent. Current consensus across systematic reviews is that AI should be used as an adjunct that improves efficiency and reproducibility, with expert nuclear medicine physician oversight remaining necessary given model 'black box' limitations and performance variability.

## Fields

- Kind: Technology
- Last checked: 2026-09-22
- Also known as: deep learning PET/SPECT; aPROMISE
- Tags: AI; imaging; PSMA
- Principle: Neural networks trained on large sets of scans with expert-drawn reference contours learn to recognise the imaging patterns of disease directly from pixel data, so a new scan can be automatically segmented, quantified or flagged in seconds by pattern-matching against what the network learned, rather than a person tracing every lesion by hand.
- Since: Deep-learning segmentation tools for PET/SPECT emerging from the mid-2010s; clinical deployment of platforms such as aPROMISE from the early 2020s

## Sources

- PSMA PET evaluation with a deep-learning platform compared with a standard viewer and histopathology (J Nucl Med 2025): https://pubmed.ncbi.nlm.nih.gov/41101977/
- Artificial intelligence across oncologic theranostics: evidence for patient stratification, dosimetry and adaptive radiopharmaceutical therapy (Front. Nucl. Med. 2026): https://www.frontiersin.org/journals/nuclear-medicine/articles/10.3389/fnume.2026.1935247/full
- The value of artificial intelligence in PSMA PET: a pathway to improved efficiency and results, systematic review (2025): https://pubmed.ncbi.nlm.nih.gov/40444499/
- Deep learning-based PSMA PET segmentation repeatability: test-retest analysis (2026): https://pubmed.ncbi.nlm.nih.gov/41166032/

## Connected records

- technologies: [Monte Carlo dosimetry](https://nuclide.cc/technologies/monte-carlo-dosimetry/), [PSMA PET](https://nuclide.cc/technologies/psma-pet/), [Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)](https://nuclide.cc/technologies/quantitative-imaging-biomarkers/), [Radiomics](https://nuclide.cc/technologies/radiomics/)
- isotopes: [Fluorine-18](https://nuclide.cc/isotopes/f-18/), [Gallium-68](https://nuclide.cc/isotopes/ga-68/), [Yttrium-90](https://nuclide.cc/isotopes/y-90/)

---
JSON: https://nuclide.cc/api/v1/entities/ai-in-nuclear-medicine.json